SpyGlass Pharma, Inc.: updates and filings

SGPNASDAQHealthcare · Surgical & Medical Instruments & Apparatus

Price

$30.43

November 20, 2026Market cap $1.0B

What Ploutos Investor adds for SpyGlass Pharma

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 2 fiscal years, from 2024
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 26, 2026 latest annualNov 12, 2026 latest quarterly
  • Nov 18, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Nov 12, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 12, 2026Results of operations, other material events
    Form8-K
  • Oct 19, 2026Other material events
    Form8-K
  • Oct 1, 2026Regulation FD disclosure, other material events
    Form8-K
  • Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 6, 2026Results of operations
    Form8-K
  • May 14, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 14, 2026Results of operations
    Form8-K
  • Mar 26, 2026Annual reportfor the period to Dec 31, 2025
    Form10-K
  • Mar 26, 2026Results of operations
    Form8-K
  • Mar 9, 2026Other material events
    Form8-K
  • Feb 17, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Feb 17, 2026Over-5% holder statement (active)
    FormSCHEDULE 13D
  • Feb 13, 2026Over-5% holder statement (active)
    FormSCHEDULE 13D
  • Feb 13, 2026Over-5% holder statement (active)
    FormSCHEDULE 13D
  • Feb 13, 2026Officer or director change
    Form8-K
  • Feb 13, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Feb 10, 2026Over-5% holder statement (active)
    FormSCHEDULE 13D
  • Feb 9, 2026Officer or director change, amended articles or bylaws, Regulation FD disclosure
    Form8-K
  • Feb 6, 2026Shares registered for employees
    FormS-8
  • Feb 5, 2026Exchange certification of a listing
    FormCERT
  • Feb 5, 2026Securities listed on an exchange
    Form8-A12B
  • Jan 30, 2026Filing
    FormEFFECT
  • Jan 29, 2026Correspondence with the SEC
    FormCORRESP

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jun 5, 2019.

The full analysis

What do SpyGlass Pharma's filings show?

The filings are where every one of SpyGlass Pharma's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.